FreeTheAI

I-Tech AB Reports 19% Q3 Sales Growth as Net Profit Rises to SEK 11.6 Million

BullishMedium impact
ITECHSEK 72.40 1.12%

I-Tech AB (ITECH) reported a 19% year-over-year increase in third-quarter net sales to SEK 48.8 million. Operating profit reached SEK 13.3 million, yielding an operating margin of 27%. Net profit for the period rose 24% year-over-year to SEK 11.6 million.

The solid results reflect ongoing sales growth and stable profit margins. Strong cash generation continued during the quarter, with operating cash flow hitting SEK 13.3 million and bringing total cash reserves to SEK 177 million. Following the report, company shares increased by 1.12% to 72.4 SEK.

Attention now turns to key regulatory developments in Europe. An EU review vote on medetomidine scheduled between October 7 and October 21 serves as a major upcoming milestone for the company.

Key points

  • Third-quarter net sales rose 19% year-over-year to SEK 48.8 million.
  • Operating profit reached SEK 13.3 million with a 27% operating margin.
  • Net profit climbed 24% year-over-year to SEK 11.6 million.
  • Cash reserves reached SEK 177 million following SEK 13.3 million in quarterly operating cash flow.
  • An EU regulatory review vote on medetomidine is set for October 7–21.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

What were I-Tech AB's Q3 2026 sales and profit numbers?

I-Tech AB reported Q3 net sales of SEK 48.8 million, up 19% year-over-year, and net profit of SEK 11.6 million, up 24%.

What is I-Tech AB's current cash balance?

At the end of the third quarter, I-Tech AB held SEK 177 million in cash, backed by SEK 13.3 million in operating cash flow.

What upcoming catalyst is facing I-Tech AB?

An EU review vote on medetomidine scheduled between October 7 and October 21 is a key regulatory event for the company.